資源描述:
《婦膚康噴霧劑治療混合性陰道感染的臨床研究》由會員上傳分享,免費在線閱讀,更多相關內容在工程資料-天天文庫。
1、婦膚康噴霧劑治療混合性陰道感染的臨床研究【摘要】目的:觀察分析婦膚康噴霧劑治療混合性陰道感染的臨床療效。方法:選取從2009年6月至2014年6月收治的混合性陰道感染患者共140例。隨機將患者分為觀察組和對照組,其中觀察組患者采用婦膚康噴霧劑聯(lián)合制霉素治療,對照組患者則采用常規(guī)甲硝唑和制霉素治療。結果:對比兩組患者在停止用藥14d后的復診結果。其中BV+VVC感染觀察組有效率為85.7%,對照組為66.7%;BV+TV感染觀察組的治療有效率為94.4%,對照組為64.7%;而TV+VVC感染觀察組患者的治療有效率為91.0
2、%,對照組為72.7%;BV+VVC+TV混合感染觀察組治療有效率為92.3%,對照組為50.0%。兩組患者在接受治療后的30d復診結果,其中BV+VVC感染觀察組有效率為89.3%,對照組為50.0%;BV+TV感染觀察組的治療有效率為100%,對照組為41.2%;而TV+VVC感染觀察組患者的治療有效率為100.0%,對照組為50.0%;BV+VVC+TV混合感染觀察組治療有效率為92.3%,對照組為41.7%。對比觀察組和對照組患者藥物不良反應,其中觀察組總體不良反應發(fā)病率為8.6%;對照組總不良反應發(fā)生率為22.9
3、%,對比有顯著性。結論:婦膚康噴霧劑能夠較好治療混合性陰道感染,不破壞陰道弱酸性環(huán)境,安全性高、復發(fā)率低,便于使用?!娟P鍵詞】婦膚康噴霧劑;混合性陰道感染;臨床研究ClinicalstudyofFufukangspraytreatmentformixedvaginalinfectionsCAOZhanhuil,YUYingl,LIUXinhua2.1.DepartmentofGynecologyandObstetrics,DongshengDistrictPeople’sHospitalofErdos,Erdos01700
4、0,China;2.DepartmentofGynecologyandObstetrics,GongliuCountyPeople’sHospital,Yili835400,China;3.DepartmentofGynecologyandObstetrics,NorthBranchofXinjiangUygurAutonomousRegionPeople’sHospital,Urumqi830054,China【Abstract】Objectives:ToobservetheclinicalefficacyofFufuk
5、angspraytreatmentofmixedvaginalinfection.Methods:140patientswithmixedvaginalinfectionsfromMarch2009toMarch2014wereselectedandrandomlydividedintoobservationgroupandcontrolgroup,inwhichtheobservationgroupweretreatedwithnystatinjointFufukangspraytreatmentandthecontro
6、lgroupreceivedconventionaltreatmentofmetronidazoleandnystatin.Results:Theresultsofsubsequentvisitsonthe14thdayafterterminatingtreatmentofbothgroupswerecompared.TheBV+VVCinfectiontreatmentrateintheobservationgroupandcontrolgroupwas85.7%and66.7%respectively;theBV+TV
7、infectiontreatmentrateintheobservationgroupandcontrolgroupwas94.4%and64.7%respectively;theTV+VVCinfectiontreatmentrateintheobservationgroupandcontrolgroupwas91.0%and72.7%respectively;theBV+VVC+TVmixedinfectiontreatmentrateintheobservationgroupandcontrolgroupwas92.
8、3%and50.0%respectively.Accordingtotheresultsofsubsequentvisitsonthe30thdayafterterminatingtreatment,theBV+VVCinfectiontreatmentrateintheobservationgroup